L.R. Hoes

TL;DR: An in vitro test based on patient-derived tumor organoids (PDOs) from metastatic lesions to identify nonresponders to standard-of-care chemotherapy in colorectal cancer (CRC) is developed and the feasibility of generating and testing PDOs for evaluation of sensitivity to chemotherapy is shown.

TL;DR: How the seven comprehensive cancer centers of Cancer Core Europe have organized their healthcare systems at an unprecedented scale and pace to make their operations ‘pandemic proof’ is reported.

TL;DR: The Drug Rediscovery protocol facilitates the defined use of approved drugs beyond their labels in rare subgroups of cancer, identifies early signals of activity in these subgroups, accelerates the clinical translation of new insights into the use of anticancer drugs outside of their approved label, and creates a publicly available repository of knowledge for future decision-making.

TL;DR: The SENSOR trial as mentioned in this paper evaluated the feasibility of patient-derived organoids to allocate patients for treatment with off-label or investigational agents, and the primary endpoint was an objective response rate of ≥20%.

TL;DR: The WIDE study aims to investigate the feasibility and validity of WGS-based diagnostics in clinical practice, and yield the optimal conditions under which WGS can be implemented in a routine molecular diagnostics setting.